Introduction to B-FREE Chronic Babesiosis Study
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a dedicated pharmaceutical company focused on developing innovative treatments for vector-borne diseases, is pleased to announce the opening of the clinical site for its B-FREE Chronic Babesiosis Study. Conducted at the prestigious Cohen Center for Recovery from Complex Chronic Diseases, this study aims to examine tafenoquine, a drug previously approved for malaria prevention, in patients suffering from chronic babesiosis.
Study Overview
The B-FREE study is designed as a 90-day trial that will closely monitor changes in general fatigue levels among patients diagnosed with chronic babesiosis after receiving tafenoquine treatment. The study will run for a duration of approximately 12 months, with an enrollment goal of up to 100 patients. This research is particularly significant given the staggering estimates of unmet medical needs, which suggest there are between 4,400 and 190,000 cases of chronic babesiosis within the United States annually, yet treatments remain lacking.
Understanding Babesiosis and its Impact
Chronic babesiosis is caused by the Babesia parasites, leading to debilitating fatigue and associated symptoms that severely impact the quality of life for affected individuals. Current assessments indicate that around 4,400 people in the U.S. suffer from severe fatigue due to chronic babesiosis, but this figure could rise dramatically if more comprehensive testing identifies additional cases. Understanding the full scope of this disease is essential not only for developing effective treatments but also for acknowledging the plight of those affected.
The Role of Tafenoquine
Tafenoquine, commercially known as ARAKODA®, has been approved for malaria prophylaxis, yet it has not been validated for treating babesiosis. The current study will explore the safety and efficacy of this regimen over a 90-day treatment period, with primary outcome measures focusing on the resolution of fatigue in participating patients. This novel approach to studying tafenoquine's potential benefits in chronic babesiosis is a significant step forward for both the pharmaceutical company and the broader medical community.
Insights from Leadership
Geoff Dow, PhD, CEO of 60 Degrees Pharmaceuticals, expressed enthusiasm regarding the study's launch, emphasizing the necessity for better understanding the impact of chronic babesiosis and the potential improvements tafenoquine could bring to patients’ lives. Dr. Dow indicated, “This study is vital in illustrating both the therapeutic benefits of tafenoquine and the broader implications for chronic babesiosis diagnosis and treatment.”
Perspectives from Researchers
Principal Investigator David Putrino also highlighted the severe challenges patients face. He noted, “This study is an important step toward better understanding the diagnosis of chronic babesiosis and developing new treatments.” Additionally, CoRE Scientific Director Amy Proal, PhD, expressed pride in being part of the tafenoquine trial team, underlining the urgency of finding approved treatment options for the daunting needs of patients suffering from chronic babesiosis.
Advancements and Future Steps
The B-FREE study aims to provide crucial insights into the presence and confirmation of Babesia infection through rigorous testing methods. The findings will not only inform clinical practices but will also help to define the patient population that could benefit from future interventions using tafenoquine. These results are set to redefine the market understanding and highlight the true dimensions of chronic babesiosis as a critical health concern.
About 60 Degrees Pharmaceuticals
Founded in 2010, 60 Degrees Pharmaceuticals has committed itself to advancing public health through the development of novel therapeutics aimed at vector-borne diseases. The company made significant strides when it received FDA approval for its leading drug, ARAKODA®, in 2018 for malaria prevention. As the company continues to innovate, it actively engages with research institutions worldwide to enhance treatment possibilities and address unmet needs in the medical field.
Frequently Asked Questions
What is the purpose of the B-FREE study?
The B-FREE study aims to evaluate the efficacy of tafenoquine in reducing fatigue and eradicating Babesia parasites in patients with chronic babesiosis.
Who can participate in the study?
The study will enroll patients diagnosed with chronic babesiosis who have experienced severe fatigue for at least six months.
How long will the B-FREE study take?
The trial will last approximately 12 months and evaluate outcomes over a 90-day treatment period.
What is tafenoquine's current status?
Tafenoquine, branded as ARAKODA®, is approved for malaria prevention but not for treating babesiosis.
Who is leading the B-FREE study?
The study is led by Principal Investigator David Putrino, along with contributions from the scientific community at Mount Sinai.
